Literature DB >> 24395385

p66Shc longevity protein regulates the proliferation of human ovarian cancer cells.

Sakthivel Muniyan1, Yu-Wei Chou1, Te-Jung Tsai1,2, Paul Thomes1, Suresh Veeramani1, Benedict B Benigno3, L DeEtte Walker4, John F McDonald4, Shafiq A Khan5, Fen-Fen Lin1, Subodh M Lele6, Ming-Fong Lin1,7,8,9.   

Abstract

p66Shc functions as a longevity protein in murine and exhibits oxidase activity in regulating diverse biological activities. In this study, we investigated the role of p66Shc protein in regulating ovarian cancer (OCa) cell proliferation. Among three cell lines examined, the slowest growing OVCAR-3 cells have the lowest level of p66Shc protein. Transient transfection with p66Shc cDNA expression vector in OVCAR-3 cells increases cell proliferation. Conversely, knock-down of p66Shc by shRNA in rapidly growing SKOV-3 cells results in decreased cell growth. In estrogen (E2)-treated CaOV-3 cells, elevated p66Shc protein level correlates with ROS level, ErbB-2 and ERK/MAPK activation, and cell proliferation. Further, the E2-stimulated proliferation of CaOV-3 cells was blocked by antioxidants and ErbB-2 inhibitor. Additionally, in E2-stimulated cells, the tartrate-sensitive, but not the tartrate-resistant, phosphatase activity decreases; concurrently, the tyrosine phosphorylation of ErbB-2 increases. Conversely, inhibition of phosphatase activity by L(+)-tartrate treatment increases p66Shc protein level, ErbB-2 tyrosine phosphorylation, ERK/MAPK activation, and cell growth. Further, inhibition of the ERK/MAPK pathway by PD98059 blocks E2-induced ERK/MAPK activation and cell proliferation in CaOV-3 cells. Moreover, immunohistochemical analyses showed that the p66Shc protein level was significantly higher in cancerous cells than in noncancerous cells in archival OCa tissues (n = 76; P = 0.00037). These data collectively indicate that p66Shc protein plays a critical role in up-regulating OCa progression.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  ErbB-2 signaling; ROS; estrogen; p66Shc; tyrosine phosphatase

Mesh:

Substances:

Year:  2014        PMID: 24395385      PMCID: PMC4117819          DOI: 10.1002/mc.22129

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  50 in total

1.  Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors.

Authors:  P Lindgren; T Bäckström; C G Mählck; M Ridderheim; S Cajander
Journal:  Int J Oncol       Date:  2001-07       Impact factor: 5.650

2.  The p66shc adaptor protein controls oxidative stress response and life span in mammals.

Authors:  E Migliaccio; M Giorgio; S Mele; G Pelicci; P Reboldi; P P Pandolfi; L Lanfrancone; P G Pelicci
Journal:  Nature       Date:  1999-11-18       Impact factor: 49.962

3.  Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells.

Authors:  T C Meng; M S Lee; M F Lin
Journal:  Oncogene       Date:  2000-05-18       Impact factor: 9.867

4.  Human prostatic acid phosphatase has phosphotyrosyl protein phosphatase activity.

Authors:  M F Lin; G M Clinton
Journal:  Biochem J       Date:  1986-04-15       Impact factor: 3.857

5.  Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo.

Authors:  Tzu-Ching Meng; Toshiyuki Fukada; Nicholas K Tonks
Journal:  Mol Cell       Date:  2002-02       Impact factor: 17.970

6.  Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells.

Authors:  M F Lin; M S Lee; X W Zhou; J C Andressen; T C Meng; S L Johansson; W W West; R J Taylor; J R Anderson; F F Lin
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

Review 7.  Signaling via Shc family adapter proteins.

Authors:  K S Ravichandran
Journal:  Oncogene       Date:  2001-10-01       Impact factor: 9.867

8.  Menopausal hormone replacement therapy and risk of ovarian cancer.

Authors:  James V Lacey; Pamela J Mink; Jay H Lubin; Mark E Sherman; Rebecca Troisi; Patricia Hartge; Arthur Schatzkin; Catherine Schairer
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas.

Authors:  Ming-Shyue Lee; Tsukasa Igawa; Siu-Ju Chen; Dana Van Bemmel; Jamie S Lin; Fen-Fen Lin; Sonny L Johansson; Judith K Christman; Ming-Fong Lin
Journal:  Int J Cancer       Date:  2004-02-20       Impact factor: 7.396

10.  Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer.

Authors:  Pamela A Davol; Robert Bagdasaryan; Gerald J Elfenbein; Abby L Maizel; A Raymond Frackelton
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

View more
  6 in total

Review 1.  Healthful aging mediated by inhibition of oxidative stress.

Authors:  Stephen F Vatner; Jie Zhang; Marko Oydanich; Tolga Berkman; Rotem Naftalovich; Dorothy E Vatner
Journal:  Ageing Res Rev       Date:  2020-10-19       Impact factor: 10.895

Review 2.  p66Shc as a switch in bringing about contrasting responses in cell growth: implications on cell proliferation and apoptosis.

Authors:  Sahar S Bhat; Deepak Anand; Firdous A Khanday
Journal:  Mol Cancer       Date:  2015-04-08       Impact factor: 27.401

3.  MS-5, a Naphthalene Derivative, Induces the Apoptosis of an Ovarian Cancer Cell CAOV-3 by Interfering with the Reactive Oxygen Species Generation.

Authors:  Eunsook Ma; Seon-Ju Jeong; Joon-Seok Choi; Thi Ha Nguyen; Chul-Ho Jeong; Sang Hoon Joo
Journal:  Biomol Ther (Seoul)       Date:  2019-01-01       Impact factor: 4.634

4.  Prognostic value and prospective molecular mechanism of miR-100-5p in hepatocellular carcinoma: A comprehensive study based on 1,258 samples.

Authors:  Qing-Lin He; Shan-Yu Qin; Lin Tao; Hong-Jian Ning; Hai-Xing Jiang
Journal:  Oncol Lett       Date:  2019-10-04       Impact factor: 2.967

5.  p66ShcA functions as a contextual promoter of breast cancer metastasis.

Authors:  Kyle Lewis; Alex Kiepas; Jesse Hudson; Julien Senecal; Jacqueline R Ha; Elena Voorand; Matthew G Annis; Valerie Sabourin; Ryuhjin Ahn; Rachel La Selva; Sébastien Tabariès; Brian E Hsu; Matthew J Siegel; Matthew Dankner; Eduardo Cepeda Canedo; Mathieu Lajoie; Ian R Watson; Claire M Brown; Peter M Siegel; Josie Ursini-Siegel
Journal:  Breast Cancer Res       Date:  2020-01-15       Impact factor: 6.466

6.  Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.

Authors:  Raghupathy Vengoji; Pranita Atri; Muzafar A Macha; Parthasarathy Seshacharyulu; Naveenkumar Perumal; Kavita Mallya; Yutong Liu; Lynette M Smith; Satyanarayana Rachagani; Sidharth Mahapatra; Moorthy P Ponnusamy; Maneesh Jain; Surinder K Batra; Nicole Shonka
Journal:  J Exp Clin Cancer Res       Date:  2021-10-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.